MED9

MED9 is an evolutionarily conserved subunit of the Mediator transcriptional coactivator complex that bridges gene-specific regulators to the RNA polymerase II machinery (PMID:9891034, PMID:15175163). In yeast, Med9 (Cse2) resides in the Rgr1 subcomplex as part of a discrete Med9/10 submodule, where it is specifically required for Bas1/Bas2-mediated activation of amino acid biosynthetic genes and for repression of a distinct subset of genes (PMID:9891034, PMID:11470794). This dual activating and repressive function is linked to physical and genetic interactions with the Srb10/11 kinase module, positioning the Med9 submodule as a contact point through which Mediator exerts negative control over polymerase II (PMID:11555651). Med9 does not transmit activator signals through a TFIIE-bypass pathway, distinguishing its mechanism from that of Med2 and Pgd1 (PMID:12558798). Structurally, Med9 forms a heterodimer with Med4 that, paired with the Med7/Med21 heterodimer, constitutes the central tetramer at the core of the Mediator middle module (PMID:23939621). The mammalian ortholog (FLJ10193) is a bona fide consensus subunit of purified Mediator, sharing structural and functional features with yeast Cse2 (PMID:14638676, PMID:15175163).

1. 1999 Medium

   Established that Med9/Cse2 is a Mediator subunit with an activator-specific role rather than a general coactivator function, showing that distinct Mediator subunits serve distinct regulatory programs.

   Evidence Cloning, mutant isolation, and differential display/Northern analysis of mRNAs in wild-type vs. Mediator mutant yeast

   PMID:9891034

   Open questions at the time

   • Direct molecular contact between Med9 and Bas1/Bas2 not demonstrated
   • Mechanism of activator selectivity unresolved
2. 2001 Medium

   Defined Med9 as part of a discrete Med9/10 submodule within the Rgr1 subcomplex that mediates both activation and repression, and connected this submodule to the Srb10/11 kinase module, explaining how Mediator can exert negative control over RNA polymerase II.

   Evidence Recombinant protein interaction assays, genetic epistasis, in vitro transcription, genome-wide expression analysis in med9 deletion mutants, and GST pull-down of the repressor Tup1

   PMID:11470794 PMID:11555651

   Open questions at the time

   • Precise Med9 residues contacting Srb10/11 not mapped
   • Whether activator/repressor competition acts directly on Med9 not shown
3. 2003 Medium

   Showed that Med9 does not signal through a TFIIE-bypass pathway, narrowing the mechanistic route by which it transmits regulatory information compared to other Mediator subunits.

   Evidence Artificial recruitment of Ace1-Med9 fusion to the CUP1 promoter with genetic TFIIE-requirement assays and ChIP

   PMID:12558798

   Open questions at the time

   • Informative negative result; the actual signal-transmission pathway used by Med9 remains undefined
   • Single study without orthogonal confirmation
4. 2003 Medium

   Identified the mammalian FLJ10193 product as a Mediator subunit orthologous to yeast Cse2, extending the conservation of Med9 function to mammals.

   Evidence Tandem mass spectrometry of purified rat Mediator fractions

   PMID:14638676

   Open questions at the time

   • Functional role of mammalian MED9 not tested
   • Ortholog naming inconsistent with later nomenclature
5. 2004 High

   Confirmed mammalian MED9 as a consensus Mediator subunit across independent purifications, solidifying its status as a stable component of the complex.

   Evidence MudPIT proteomics of six independent immunoaffinity-purified mammalian Mediator preparations

   PMID:15175163

   Open questions at the time

   • Does not address mammalian-specific function or target genes
   • Submodule assignment in mammals not resolved
6. 2013 Medium

   Placed Med9 structurally within the central tetramer of the Mediator middle module as a Med4 heterodimer partner, providing an architectural basis for its position in the complex.

   Evidence Cross-linking mass spectrometry combined with crystal structures and homology models of the yeast middle module

   PMID:23939621

   Open questions at the time

   • No mutagenesis validation of the Med4/Med9 interface
   • Structural model does not link architecture to the activation/repression functions

• How the Med9 submodule mechanistically couples activator binding, Srb10/11 kinase activity, and polymerase II regulation in a single integrated pathway remains unresolved, as does the function of mammalian MED9 beyond complex membership.
• No direct mammalian MED9 functional assays in the corpus
• Mechanism linking Med9 architecture to gene-specific output undefined